INTRODUCTION
Evolution has adapted us more poorly to fight cancer compared with almost any other disease, and until recent years, approaches to treatment of cancer had changed little. Physical removal of the tumor by surgery remains an important first-line treatment but lacks effectiveness in the face of highly aggressive or invasive cancers, cancers that are difficult to detect, or those that have reached a metastatic stage. Radiotherapy and chemotherapy are the conventional second-line treatments; however, both are nonspecific to the tumor tissue. They are generally toxic to healthy tissue and, notably for DNA-directed drugs such as cisplatin (cisdiamminedichloroplatinum), may ultimately be carcinogenic in their own right. 1, 2 This review deals with a novel class of targeted drugs developed by several independent groups over the last few years: small-molecule inhibitors of the antiapoptotic protein Bcl-2 (B-cell lymphoma/leukemia-2). The antitumor and antiangiogenic potential of these compounds will be discussed. In the literature, the term Bcl-2 inhibitor encompasses various drugs that bind the antiapoptotic Bcl-2 family members with more or less efficacy. None of the compounds here discussed are specific to only one member of the Bcl-2 family.
BCL-2-RELATED PROTEIN FAMILY
Bcl-2 is a 26-kDa protein localized to the mitochondria and endoplasmic reticulum that acts as a key inhibitor of apoptosis. Expression of Bcl-2 is essential for growth of certain tumor cell lines in vitro and has been found upregulated in a variety of tumor types in vivo. [3] [4] [5] The interactions of other Bcl-2 family members and their role in modulating Bcl-2 functions have been reviewed, 6 ,7 and a detailed discussion of such is beyond the scope of this review. A brief description here may aid the appreciation of drug actions. Bcl-2 and other members of the family are primary regulators of apoptosis (Fig 1) . They maintain a balance within the cell that is biased toward survival. Bcl-2 structure consists of five domains, Bcl-2 homology (BH) domains 1 to 4 plus a transmembrane domain (Fig 2) . The other Bcl-2 family members bear four or fewer of these domains and display varying degrees of homology (Fig 2) . The BH1-3 domains can form a labile hydrophobic groove, on tertiary folding, that allows binding of other molecules via their own BH3 domain. This
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hydrophobic groove is called the BH3-binding domain. In general terms, these domains define the functionality of three groups within the Bcl-2 family: two groups of either proapoptotic or antiapoptotic effector molecules bearing multiple BH domains and one group of facilitator or potentiator molecules bearing only the BH3 domain (BH3-only proteins; Fig 2) . The proapoptotic effectors Bax and Bak form oligomeric pores in the mitochondrial membrane that allow egress of apoptotic signaling molecules, whereas the antiapoptotic effectors Bcl-2, Bcl-x L , Mcl-1, and Bfl-1/A1 bind to Bax or Bak and inhibit functional oligomerization. The proapoptotic BH3-only molecules may interact with the effector molecules to promote pore formation either by competitively inhibiting Bcl-2/Bcl-x L /Mcl-1, binding to Bax/Bak, or by directly promoting Bax/Bak oligomerization. 6, 8 There are a number of models, variations on the above theme, proposed to explain the interaction of these proteins and how, or even whether, they induce apoptosis signaling via the mitochondria. Exactly how this happens is unclear in real cellular models at this time (see Skommer et al 6 for further discussion).
BCL-2: ROLE IN ANGIOGENESIS AND TUMOR STATUS
Angiogenesis is the mechanism by which blood vessels form from existing vasculature. 9 It is fundamental to normal growth and development and as part of the physiologic response to wounding. Hyperplastic cell growth both encourages and requires formation of new blood vessels, as evidenced by the generally high vascularity of tumors. Indeed, beyond 1-to 2-mm size, tumors cannot sustain expansion without induction of angiogenesis. Simple diffusion of nutrients is clearly insufficient to maintain tumor growth. 10 Three of the primary activators of angiogenesis are vascular endothelial growth factor (VEGF), CXCL1 (growth-related oncogene, GRO-alpha), and CXCL8 (interleukin-8), promoting endothelial cell survival and proliferation.
11,12
The involvement of Bcl-2 as a proangiogenic signaling molecule is only now becoming clearer for both tumor cells and vascular endothelial cells (Fig 1) . Indeed it has long been recognized that both Bcl-2 and Bfl-1/A1 are mediators of protection for endothelial cells, 13 although Bfl-1/A1 seems to perform a rapid, and more transient, function than Bcl-2, potentially related to inflammatory response.
13,14
Although modulation of Bcl-2 in endothelial cells has been shown to affect angiogenesis in vitro and in vivo (discussed further in this paragraph and in Bcl-2 Inhibitors as Antiangiogenic Agents), little is known about the molecular mechanisms involved. Stimulation of the VEGF pathway results in increased expression of Bcl-2 in both tumor cells 15 and endothelial cells. 13, 16, 17 Bcl-2 upregulation in turn increases VEGF expression in endothelial cells and in tumor cells of various lineages.
18-20 Notably, Bcl-2 upregulation induces expression of the proangiogenic chemokines CXCL1 and CXCL8 through activation of the NF-kB signaling pathway in endothelial cells. 16, 21 It has recently been shown in human tumor biopsies that Bcl-2 is massively upregulated in head and neck squamous cell carcinoma-associated endothelial cells compared with endothelial cells in normal oral mucosa. 20 In this study, it was also demonstrated in vivo that factors secreted by endothelial cells, in response to modulation of Bcl-2 expression levels in neovascular endothelial cells, have a direct effect on tumor cell Role of Bcl-2 in tumor cell and endothelial cell apoptosis and survival. Diagram depicts the involvement of Bcl-2 in tumor cell and endothelial cell function, as well as in the regulation of cross-talks between the two cell types. Bcl-2 is a pivotal checkpoint in the apoptotic pathway, inhibiting the proapoptotic actions of Bax and Bak. Both Bcl-2 expression and hypoxia may result in vascular endothelial growth factor (VEGF) production, which is secreted by the tumor cell. Endogenous VEGF can bind to VEGF receptor 1 (VEGFR1) on tumor cells sending a prosurvival signal, upregulating Bcl-2 production, or can also bind to VEGFR2 on endothelial cells, promoting cell survival and stimulating proliferation and angiogenesis via Bcl-2-dependent pathways. 
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www.jco.org growth. 20 Additionally, the authors showed expression of VEGF to be significantly attenuated in vitro by small inhibitory RNA directed against Bcl-2, in both Bcl-2 overexpressing and control endothelial cells. 20 It is clear that disruption of the Bcl-2 pathway may be expected to affect angiogenesis, both directly by inhibiting function of endothelial cells and, as many cancers display increased Bcl-2 expression, by concomitant reduction in levels of endothelial-stimulating factors, such as VEGF, CXCL1, and CXCL8 (Fig 1) . Recently, endotheliumtargeted Bcl-2 overexpression was shown to induce disruption of the blood vessel architecture and induce embryonic lethality in transgenic mice. 22 This effect was limited to the microvasculature and related to a reduction in endothelial apoptosis, thus directly linking Bcl-2 levels during development to angiogenic function.
22
It should be noted that the clinical picture of Bcl-2 involvement in cancer progression or patient survival is unclear, with different studies finding varying degrees of correlation between Bcl-2 expression and disease severity or prognosis, both within and between cancer types. 23, 24 Moreover, there is no clear reason why Bcl-2 expression, as a negative or positive prognostic factor, should bear any relation to whether Bcl-2 is considered as a beneficial therapeutic target. One example of this dichotomy is that of small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC). Meta-analysis of the data from 28 clinical studies indicated that Bcl-2 expression was associated with good prognosis in NSCLC but had no correlation with disease state in SCLC. 25 Furthermore, some individual studies have indeed shown correlation between Bcl-2 or Bcl-x L expression and poor disease prognosis in NSCLC. 26, 27 However, in vitro and in vivo studies consistently correlate increased Bcl-2 or Bcl-x L expression with tumor aggression and tumor cell line resistance to chemotherapeutic drugs. [28] [29] [30] They have further shown regression and reversal of drug resistance, by treatment with Bcl-2 family inhibitors, in SCLC tumors and others. 29, 30 The disparity between tumor expression and therapeutic potential may result from varying methods of analysis, but may also be explained at the cellular level. This is illustrated by two studies. In the first, an acute lymphoblastic leukemia cell line treated with VEGF expressed a phosphorylated form of Bcl-2, and apoptosis was reduced.
31,32 The expression of nonphosphorylatable Bcl-2 in these cells prevented this antiapoptotic effect. In contrast, the same authors 32 also showed that VEGF-induced phosphorylation of Bcl-2 did not protect chronic lymphoblastic leukemia cells under similar conditions. Expression levels and post-translational modification of other pro-or antiapoptotic proteins, in particular the BH3-only proteins, may also account for the apparent differences. [33] [34] [35] Furthermore, inactivation of Bcl-x L by de-amidation occurs in response to common chemotherapeutic drugs, such as cisplatin. 36 With this number of variables, it is clear that simply looking at the expression level of Bcl-2 alone in a tumor is insufficient to predict the benefits of anti-Bcl-2 therapy. Profiling the expression of many specific markers within a tumor may provide a better indication for the suitability of therapies targeting individual pathways, but this analysis is not routinely performed. Accordingly, quantifiable RNA analysis of gene expression and antibody arrays or Western blot analysis of proteins could usefully supplement immunohistochemical data from tumor biopsies in future studies. Thus, at this stage, it is difficult to predict which cancers would benefit most from treatment with Bcl-2 inhibitors and in combination with which conventional therapies.
BCL-2 INHIBITORS AS ANTITUMOR AGENTS
Both internal signaling and external stimuli may alter the complex balance toward apoptosis by activation of the proapoptotic BH3-only molecules and subsequent inactivation of Bcl-2/Bcl-x L , thus tipping the balance in favor of apoptosis. Much research has been carried out attempting to exploit the BH3-binding permissive network toward development of Bcl-2/Bcl-x L inhibitors that result in activation of Bax and Bak. A number of genetic and pharmacologic approaches have been used to this end. Targeting Bcl-2 family RNA has shown positive results, and oblimersen (Genasense; G3139; Genta Inc, Berkeley Heights, NJ), an anti-Bcl-2 antisense oligonucleotide, has reached phase III clinical trials in combination therapy. 37 Peptide-based drugs have also been shown both to attenuate Bcl-2 activity 38 and to activate Bax. 8 However, nonpeptidic small-molecule inhibitors of signaling pathways are likely to remain developmental drugs of choice for the short to medium term, particularly because of the inherent low antigenicity of nonprotein organic compounds. In addition, the ease and plasticity of molecular modification allows ready tailoring of putative drugs. This last allows manipulation of compounds to aid routespecific delivery, increase bioavailability, increase target affinity, and, hopefully, to reduce patient drug load. This is a relatively new area for Bcl-2 inhibitors, and currently few compounds have been under developmental and clinical study since the start of the decade. Only within the last 6 to 12 months have publications appeared on a newer, larger group of compounds. The established compounds with available experimental data are discussed next in the context of cancer and angiogenesis. In this review, these compounds have been categorized as derived from natural sources (see "From Nature") or compounds that were designed in laboratories (see "From Desktop to Benchtop to Bedside").
From Nature
The first drugs to be examined for therapeutic potential in many diseases are generally pre-existing compounds that may be in use for ostensibly unrelated purposes. Even where they have been examined for anticancer activity, their molecular targets are rarely known in advance. This has certainly been true for Bcl-2 inhibitors. The health benefits of green and black tea polyphenols, in particular catechins and theaflavins, have been touted as almost the nearest equivalent to natural cure-alls. Indeed they do seem to have remarkably broad therapeutic properties according to the literature 39-42 and are commonly listed as small-molecule Bcl-2 inhibitors in cancer-related publications. Work from the Burnham Institute for Medical Research, using nuclear magnetic resonance structural data and binding displacement studies, provided clear evidence of binding between green or black tea polyphenols and Bcl-2 and Bcl-x L .
43,44 They also readily induce apoptosis in tumor cells in vitro and in vivo. [45] [46] [47] [48] However, tea polyphenols, and in particular the major active component epigallocatechin-3-gallate (EGCG; Fig 3F, Table 1 ), have been shown to act as highly specific ligands for a variety of cellular pathways other than those of Bcl-2. These include inhibition of platelet-derived growth factor receptor ligand binding, 71 tyrosine phosphorylation of the Her/Neu epidermal growth factor receptor, 72 and signaling by the metastasis-associated 67-kDa laminin receptor. 73 Expression of this last receptor conferred specific responsiveness on cancer cells to the growth inhibitory effects of EGCG and bound EGCG with a Kd of 39.9 nmol/L. 73 In addition to these extracellular targets, tea polyphenols (EGCG in particular) have been shown to bind to, or directly affect, the pathways of a number of signaling molecules, including cyclooxygenase and retinoblastoma protein. 74, 75 These all may have equal claim, alongside Bcl-2, to be the cancer cell inhibitory targets for this class of compounds. Therefore, although tea polyphenols remain an exciting area for investigation as active antitumor-cell drugs, it is difficult to accurately describe them as primarily acting via the Bcl-2 pathway.
The other major natural derivative in this class, gossypol, was isolated from the cotton plant and has been well studied as a contraceptive for human males. 76 However, gossypol, and in particular the (Ϫ)-gossypol enantiomer (AT-101; Ascenta Therapeutics Inc, Malvern, PA; Fig 3C, Table 1 ), was found to bind to Bcl-2 and Bcl-x L through fluorescence-based ligand competition assay and nuclear magnetic resonance binding analysis. 49 In contrast with tea polyphenols, there is a preponderance of evidence to suggest that the Bcl-2 family is a specific target of gossypol for induction of apoptosis. Although gossypol does bind to other molecules, calcineurin, glutathione-s-transferase, and lactate dehydrogenase with good affinity, targeting the Bcl-2 pathways seems the most likely mechanism for 80, 81 Notably, in addition to a direct Bcl-2 inhibitory action, gossypol modulates Bcl-2 family balance by downregulating the antiapoptotic members of the Bcl-2 family and upregulating the proapoptotic members in a concentration and cell-line specific manner. 50, 82, 83 As a single agent, the (Ϫ)-gossypol enantiomer has shown encouraging efficacy in vivo in a head and neck cancer model. 52 (Ϫ)-Gossypol has also been shown to overcome cisplatin resistance in vitro in a head and neck cancer line. 29 Two recent in vivo studies have reported a cooperative effect for administration of (Ϫ)-gossypol in conjunction either with chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone regimen) or radiotherapy.
51,53 A significant decrease in xenograft tumor volume (cells from a patient with clinically resistant diffuse large-cell lymphoma) was observed when animals were treated with (Ϫ)-gossypol/ cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy as compared with either individual treatment alone.
Mixed results were seen for racemic gossypol in phase I/II trials, but no severe toxicity was observed, except during determination of maximum-tolerated doses, where severe emesis was the doselimiting toxicity. 57, [84] [85] [86] Currently, phase I/II clinical trials are underway for (Ϫ)-gossypol (AT-101) in single-agent treatment of relapsed B-cell malignancy. The compound is also being assessed in combination therapy with docetaxel and prednisone for hormonerefractory prostate cancer and also with an anti-CD20 antibody, rituximab, for chronic lymphocytic leukemia (see clinical trial listing at www.cancer.gov). Two further clinical trials have been approved for relapsed/refractory SCLC and newly diagnosed glioblastoma multiforme (www.cancer.gov).
Also under development are derivatives of Antimycin A, isolated from Streptomyces. Antimycin A (Fig 3G, Table 1 ) is an antifungal compound and a mitochondrial poison that targets complex III of the respiratory chain and that was shown to bind to the BH3 binding domain of Bcl-2/Bcl-x L .
43,66,67 It is highly toxic in mouse models, with a single median lethal dose of 1 mg/kg. 66, 68, 87 Although a large body of literature can be found for the parent molecule, considerably less work has been published about the newer, less toxic derivatives, in particular, 2-methoxyantimycin.
66,69,87,88 2-Methoxyantimycin has been shown to function cooperatively with paclitaxel and docetaxel to induce apoptosis, whereas the parental compound, Antimycin A, displayed synergy with the topoisomerase inhibitor SN-38 in inhibiting cell growth in a human colon cancer line. 70, 87 If the less toxic antimycin analogs can retain activity displayed in the few available studies, they may prove to be a particularly interesting drug series.
From Desktop and Benchtop to Bedside
Inspired by the potential of natural Bcl-2 inhibitors, several research groups have developed specific inhibitors of Bcl-2. Primarily, various forms of in silico and in vitro screening of combinatorial libraries, for best-fit compounds, have resulted in Bcl-2 inhibitors of varying capacity and high affinity for one or more of the Bcl-2 family of proteins. HA14-1 (Fig 3D, Table 1 ) was the first Bcl-2-binding ligand to be discovered using these computer-based screening strategies using the predicted structure of Bcl-2. 54 Both synergistic and additive effects of HA14-1, with other chemotherapeutic compounds, contributed to reversal of drug resistance in vitro in a broad variety of cell lines and treatment regimens. 56, 58, [89] [90] [91] [92] Notably, the order of treatment in a combination regimen made a profound difference in the final effect. HA14-1 acts as a radiosensitizer on LNCaP and PC3 prostate cancer cell lines with or without overexpression of Bcl-2. Synergy was only seen in the PC3 cells when HA14-1 was administered after exposure to gamma radiation, and not in the reverse order. 91 In glioblastoma cells, a 1-hour pretreatment with HA14-1 sensitized the cells to radiation in a Bcl-2, but not Bcl-x L , dependent manner. 59 Skommer et al 90 found synergy between HA14-1 and dexamethasone or doxorubicin, but not vincristine, in inhibiting B-cell lymphoma tumor cell proliferation. They observed that for HA14-1 and doxorubicin, synergistic inhibition was seen only when the Bcl-2 inhibitor was administered 24 hours before the conventional chemotherapeutic drugs, and antagonism was seen if they were administered simultaneously. In combination with the cyclindependent kinase (CDK) inhibitor flavopiridol, HA14-1 displays a similar synergy, but in this instance, only when the Bcl-2 inhibitor is administered after the CDK inhibitor. 93 It is noteworthy that the precise order of administration of HA14-1 in radiation, doxorubicin, or flavopiridol studies was important for enhancement of the inhibitory effect of HA14-1. Although not reported for all the Bcl-2 smallmolecule inhibitors, most classes of drugs display administration order preferences for optimal cooperation with other therapeutic agents. The varying results, described above, for HA14-1 in combination therapy with radiation or chemotherapeutics may be due to tumor-specific differences in target expression (Bcl-2/Bcl-x L /Mcl-1) or modulation of those proteins by whichever therapy is administered first.
Other small-molecule inhibitors of Bcl-2 began to appear after HA14-1, in particular TW-37 (TW37) and ABT-737. Both TW-37 and ABT-737 improve on HA14-1 in efficacy, having nanomolar affinities for Bcl-2. However, only TW-37 has nanomolar to low micromolar affinities for all of the major antiapoptotic members of the Bcl-2 family of proteins. TW-37 (Fig 3B, Table 1 ) represents a new class of pan-Bcl-2 protein family inhibitor. It is a BH3 mimetic developed by rational structural design using a computer-based modeling strategy. 60, 61 Apoptosis was shown to be the primary mechanism for the growth-inhibitory properties of TW-37 in the prostate cancer cell line PC3. 60 TW-37 has also been shown to effectively inhibit growth of Kaposi's sarcoma (SLK), breast cancer (MCF-7), and prostate cancer (LnCap) cell lines without inhibitory effects on human dermal fibroblasts. 55 Melanoma is particularly resistant to conventional chemotherapies.
94 TW-37 was found to be effective against melanoma-derived tumors when jointly administered with the mitogen-activated protein kinase kinase (MEK) inhibitors U0126 or CL-1040 and, to a lesser extent, as single agent both in vivo and in vitro. 62 The rationale for coadministration was that some melanomas respond poorly to mitogen-activated protein kinase inhibition, possibly through ERKmediated upregulation of the antiapoptotic Bcl-2 family of proteins. Using lentiviral-driven inhibitory RNA, the Soengas group produced a series of isogenic melanoma cell lines deficient in specific molecules of the apoptosis pathway. They identified Bcl-2, Mcl-1, and Bcl-x L as integral components of resistance to MEK inhibition. 62 They also showed synergistic inhibition of melanoma cell growth by TW-37 and the MEK inhibitors in vitro. Notably, in vivo coadministration significantly inhibited xenografted melanoma tumor growth when compared with either agent alone.
In an initial study by Oltersdorf et al, 30 ABT-737 (Fig 3E, Table  1 ) was shown to bind Bcl-2, Bcl-x L , and Bcl-w with high affinity (Ki Յ 1 nmol/L), but to have extremely low affinity for Mcl-1, Bcl-b, and A1. Indeed, the low affinity for Mcl-1 has defined part of the research into this compound, as the drug efficacy is greatly attenuated in the presence of that protein. ABT-737 was effective in delaying growth of tumors overexpressing Bcl-2. In contrast, tumors transduced with vectors inducing Mcl-1 overexpression were highly refractory to the drug. 95 Additionally, ABT-737 induced thrombocytopenia in mice in a transient and reversible manner but was nontoxic to hematopoietic progenitor cells, including megakaryocytes. 65, 96, 97 This was shown to occur via direct inhibition of platelet Bcl-x L by ABT-737, preventing binding of Bcl-x L to Bak and inducing Bak-mediated platelet apoptosis. 97 Recently, Chen et al 98 have shown that selective downregulation of Mcl-1, either by CDK inhibitors such as roscovitine or by gene silencing, synergistically increases the sensitivity of human leukemia cells to ABT-737-induced apoptosis.
Given these issues, it is notable that ABT-737 is a highly active drug in several models. It has shown antitumor efficacy, as a single agent administered intraperitoneally, in two models of lung cancer using cell lines with known sensitivity to the compound and also in models of leukemia. 30, 65 In chronic myelogenous leukemia, the Bcr/ Abl pathway promotes leukemogenesis, but the Bcr/Abl inhibitor (imatinib; Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ) induces apoptosis in affected cells via a Bcl-2/Bcl-x L -mediated pathway. 99 Coadministration of ABT-737 and imatinib to Bim/Bad double knockout Bcr/Abl-positive cells enhanced apoptosis as compared with either drug alone.
100 Thus ABT-737 seems to compensate for the loss of the BH3-only proteins Bim or Bad. It remains to be seen whether ABT-737 moves on to clinical trial, although a structurally related, orally available analog, ABT-263, is indeed entering phase I/II clinical trials for lymphocytic leukemia and SCLC 101 (www.cancer.gov). Another small-molecule inhibitor of all the major Bcl-2 antiapoptotic family proteins, GX15-070 (Obatoclax; Fig 3A; Table 1 ), was developed by Gemin X Biotechnologies Inc. (Montreal, Quebec, Canada). Although it was the first of the specifically designed Bcl-2 small-molecule inhibitor drugs to be approved in the United States for four clinical trials (www.cancer.gov) and has been under patent since 2002, little has yet been published on this compound. In one study by Campas et al, 63 GX15-070 displayed a mean half maximal effective concentration of 1.7 Ϯ 0.1 mol/L in isolated cell lines, ranging over a 48-hour period. However, this calculation of activity excluded two lines of 11, which were considered resistant to GX15-070. Therefore, reliable determination of the activity of this drug within this class of tumors must await other confirmatory studies at this time. Additive effects were reported in combination with fludarabine and chlorambucil administered with 0.5 mol/L of GX15-070. However, synergy was observed for GX15-070 administered with the proteasome inhibitor, bortezomib, and the order of administration was not reported to alter synergistic efficacy. 64, 102 In three mantle-cell lymphoma lines studied, apoptotic concentrations of GX15-070 were able to inhibit binding of immunoprecipitated Mcl-1 and Bcl-x L to Bak, resulting in mitochondrial depolarization and caspase-3 activation. The synergistic effects of GX15-070 with bortezomib on cytotoxicity in tumor cells were attributed in large part to inhibition of the Mcl-1/Bak interaction. Interestingly, they were also attributed to the inhibitory effects of GX15-070 on Mcl-1 expression, which may have countered the strong upregulation of Mcl-1 expression induced by bortezomib treatment.
64,102

BCL-2 INHIBITORS AS ANTIANGIOGENIC AGENTS
As discussed previously, Bcl-2 is intimately involved with angiogenesis through modulation of both endothelial and tumor cell signaling. Additionally, Bcl-2 inhibitors may directly induce apoptosis in angiogenically active endothelial cells in vitro, in similar fashion to their effect on tumor cells, and endothelial cell-specific apoptosis can disrupt neovascularization in vivo.
55,103 Therefore, Bcl-2 and its related signaling network becomes a logical target for antiangiogenic cancer therapy (Fig 1) . There is an emerging body of literature on the in vivo antiangiogenic effect of inhibition of the Bcl-2 family of proteins. Notably, most of what is available has been presented as unquantified immunohistochemical data. However, direct effects of Bcl-2 inhibition have been quantified in at least one study, which reported a significant reduction in microvessel vessel density after TW-37 treatment in a humanized in vivo model of angiogenesis. 55 Of other studies, the antiangiogenic effects of EGCG have been demonstrated, including a significant reduction in microvessel density within xenografted ovarian cancer cell tumors and colon cancer tumors. 48, 104 However, as discussed previously, it may be pre-emptive to use EGCG as an example of an inhibitor inducing apoptosis solely through effects on Bcl-2. (Ϫ)-Gossypol has been shown to have potential antiangiogenic efficacy in vivo when administered in conjunction with radiotherapy, although without quantification of the reported changes in vessel density. 53 In total, these reports suggest that Bcl-2-dependent vasculature may indeed be targeted, in vivo, by small-molecule inhibitors of Bcl-2. Broadening the scope of literature search, two groups have published studies using antisense oligonucleotides to inhibit Bcl-2 expression in melanoma or prostate cancer cells transfected with Bcl-2.
105,106 Anai et al 106 observed a reduction in microvessel density when the same cells were implanted as xenografts. Together, the work published to date suggests that Bcl-2 inhibition, whether by pharmacologic or genetic means, may potentially inhibit angiogenesis toward a therapeutic end.
SUMMARY AND IMPLICATIONS
There is an expanding industry devoted toward inhibiting various components of the Bcl-2 pathway using designer small-molecule drugs (mw approximately 400 to 800). These newly developed or identified compounds not only provide us with novel therapeutic approaches to cancer treatment but also deliver new tools for the analysis of the many functions of the Bcl-2 family of proteins. With our knowledge of the Bcl-2 family expanding rapidly, this specific avenue of pharmaceutical development is unlikely to slow down in the near future. It is strengthened by the proven therapeutic efficacy of both older and more recent pharmacologic agents in vivo, particularly (Ϫ)-gossypol and ABT-737, and the utility of the same compounds for dissection of apoptotic and angiogenic pathways.
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Possibly the most useful similarities shared by these drugs are their low overall toxicities in comparison with conventional cancer therapeutics and, often, their ability to synergize with those therapeutics to inhibit tumor cell survival. Although Bcl-2 smallmolecule inhibitors are not magic bullets, they do provide a new weapon for the existing anticancer arsenal. Perhaps in sniping at new sites of blood vessel growth around metastatic sites, or used in barrage with the combined force of traditional chemotherapeutics or radiotherapy, they might prove to be efficient and safe for patients with cancer. However applied, small-molecule inhibitors of Bcl-2 have marked potential for cancer research and treatment.
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